marketing agreement

Visby's single-use, fully integrated assay is designed to detect SARS-CoV-2 nucleic acid in samples collected either by a healthcare provider or self-collected.

Oncgnostics also expects the test to be approved by regulators in Canada and to be sold there by the end of the year.

BioIQ will offer Fulgent's next-generation sequencing-based coronavirus assay on its diagnostic testing platform.

The kit, developed by Gauss in collaboration with Cellex, uses a smartphone app to instruct an individual on how to collect a sample and perform the test.

Atrys Health will offer and distribute Kantaro's SARS-CoV-2 IgG antibody test kits in parts of Europe and South America.

Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.

Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.

Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.

Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.

The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.